DUBLIN – Shares in Innate Pharma SA slumped by 40 percent Thursday on news that a combination of its first-in-class antibody, lirilumab (IPH-2102/BMS-986015), which targets three inhibitory killer-cell immunoglobulin-like receptors (KIRs), and the PD-1 inhibitor Opdivo (nivolumab) failed to demonstrate efficacy in patients with squamous cell carcinoma of the head and neck (SCCHN).